Grossman Jessica D. 4

What Happened
Jessica D. Grossman, a director of Dare Bioscience, was granted a derivative award (described as an option) for 10,000 shares on 2026-06-11. The grant is reported at a $0.00 price, so the immediate cash value recorded is $0. This is a compensatory grant (award/option), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-11; grant type: Award/Option (code A); amount: 10,000 shares; price: $0.00.
• Reported as a derivative (option) in the Form 4 filing.
• Shares owned after the transaction: not stated in the provided filing.
• Vesting: the option vests in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer’s first annual meeting after the grant date, subject to continued service.
• Exercisability: the option becomes exercisable in full upon a change in control of the issuer (per footnote).
• Filing timeliness: Form 4 was filed the same day (2026-06-11), so no late filing indicated.

Context
This is a typical board compensation award and represents the right to acquire shares in the future under vesting and exercisability conditions. Such grants are common for directors and do not by themselves signal a buy or sell of stock on the open market.